Immunomedics Inc - Strategic SWOT Analysis Review

Immunomedics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - The publisher’s summarization of the company’s business strategy.
• SWOT analysis - A detailed analysis of the company’s strengths, weaknesses, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Immunomedics Inc (Immunomedics) is a biopharmaceutical company that discovers, develops, manufactures and commercializes monoclonal antibody drug conjugates for the treatment of cancer and autoimmune disorders. It offers Trodelvy, which is indicated for the treatment of metastatic triple-negative breast cancer (mTNBC) in adult patients who have been previously treated with at least two therapies for metastatic disease. The company is investigating its lead product candidate, Sacituzumab govitecan (IMMU-132) for the treatment of patients with mTNBC, metastatic urothelial cancer, hormone receptor-positive (HR+) or human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC), and others. Immunomedics is advancing IMMU-130 (labetuzumab govitecan) for colorectal cancer and IMMU-114 for hematologic cancers. It develops candidates based on its proprietary technologies namely, ADC Linker technology. Immunomedics is headquartered in Morris Plains, New Jersey, the US.

Immunomedics Inc Key Recent Developments

Oct 26, 2020: Gilead Sciences acquires Immunomedics in $21bn deal
Sep 16, 2020: Immunome announces creation of COVID-19 advisory board
Sep 14, 2020: Gilead agrees to acquire Immunomedics for $21bn
Aug 05, 2020: Immunomedics reports second quarter 2020 results and provides corporate update
May 27, 2020: Immunomedics announces leadership change and provides business update amid COVID-19

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with the publisher’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.